Nephros Overview
Is NEPH undervalued? Intrinsic value estimate stands at $-2.1.
Get informed when a big investor buys or sells
+ Follow$-2.08
Overvalued by 149.9% based on the discounted cash flow analysis.
Nephros (NEPH) currently reports a DCF fair value of $-2.1. Use the charts on this page to explore Nephros's DCF fair value history and peer comparisons.
Nephros's discounted cash flow (DCF) fair value estimate is $-2.1, about 149.9% overvalued versus the current market price. DCF models project future free cash flows and discount them back to today — so the result depends on growth, margin, and discount-rate assumptions. Use it as one valuation lens alongside multiples and peer checks on Stockcircle.
Start with the current DCF fair value of $-2.1, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Nephros, and consider following NEPH for alerts when major investors trade the stock.
Nephros is classified in the Healthcare sector. On DCF fair value, it currently shows $-2.1. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing NEPH with unrelated industries.
